Peptides for anti-aging research is not one field but five, and they share little beyond the word. Telomere and pineal peptides, mitochondrial-derived peptides, senolytics, NAD precursors and cofactors, and the growth hormone axis each address a different hallmark of aging, each has a different quality of evidence behind it, and each demands different laboratory handling. This overview separates them, compares the compounds most often specified as reference standards, and sets out the questions that determine which one belongs in a given protocol. All material referenced is supplied for laboratory research use only and none is an approved anti-aging therapy anywhere.
The aging hallmarks these compounds map onto
The useful organising frame is the hallmarks-of-aging model: telomere attrition, mitochondrial dysfunction, cellular senescence, loss of proteostasis, deregulated nutrient sensing, and stem cell exhaustion. Nearly every peptide catalogued under this goal targets one of the first four. Endpoints in the published literature follow accordingly — telomere length by qPCR or flow-FISH, mitochondrial membrane potential and oxygen consumption rate by extracellular flux analysis, senescence-associated beta-galactosidase staining and p16INK4a expression, NAD+/NADH ratio by enzymatic NAD assay or mass spectrometry, and lifespan or healthspan curves in model organisms.
Because the hallmarks are mechanistically distinct, a compound that shifts one may do nothing to the others. Papers that report a single readout and describe it as an anti-aging effect are overreaching, and the same caution applies when reading vendor material — including ours.
The classes studied
Telomere and pineal peptides
Epitalon, the tetrapeptide Ala-Glu-Asp-Gly at 390.35 Da, is the most-cited compound in this group. It came out of Vladimir Khavinson's programme in St Petersburg, which reported telomerase activation in human somatic cell culture and lifespan effects in mice and rats across a series of publications from the 1990s onward. The work is real and published, but it is concentrated in one research group and largely in Russian-language or regional journals, and independent replication outside that network is limited. Pinealon, a related tripeptide, is studied for neuronal rather than telomere endpoints. The wider Khavinson series — organ-specific short peptides such as vilon, vesugen and cortagen — follows the same pattern of a large internal literature and a thin external one.
Mitochondrial-derived peptides
MOTS-c and humanin are encoded within the mitochondrial genome rather than the nuclear genome — humanin from the 16S rRNA region, MOTS-c from the 12S. This is genuinely novel biology and the field has grown quickly since humanin's identification in 2001. MOTS-c has reported effects on AMPK activation and the folate-methionine pathway; humanin is studied for cytoprotection against apoptotic stimuli. SS-31, elamipretide, is not mitochondrially encoded but is the most clinically advanced molecule here: a cardiolipin-binding tetrapeptide that concentrates in the inner mitochondrial membrane, with completed and ongoing human trials in mitochondrial myopathy and related indications.
Senolytics
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction that keeps senescent cells alive, published in Cell in 2017 with reported clearance of senescent cells and restoration of fitness markers in aged mice. It remains a single-flagship-paper compound with limited independent follow-up, and its all-D retro-inverso construction makes it an expensive and technically unusual reagent. Small-molecule senolytics such as fisetin sit alongside it in the same protocols without sharing its mechanism.
NAD precursors and redox cofactors
NAD+ itself, along with NMN and NR as precursors, addresses the well-documented age-related decline in tissue NAD+ and its consequences for sirtuin and PARP activity. This is the best-replicated observation in the whole area, and human trials of the oral precursors consistently show that circulating NAD+ metabolites rise; what those trials have been much less able to show is a functional consequence. Glutathione is studied as the principal intracellular redox buffer rather than as an aging intervention as such.
The growth hormone axis
GH secretagogue preparations such as CJC-1295 with ipamorelin appear under this goal because GH and IGF-1 decline with age. The evidence here cuts both ways and researchers should know it: reduced IGF-1 signalling extends lifespan in nematodes, flies and mice with striking consistency, which is close to the opposite of the assumption behind restoring the axis. Any protocol using these compounds under an aging heading needs to state which side of that literature it is testing.
What the published record shows, by study type
Cell culture
In-vitro work is where the mitochondrial peptides read most cleanly. MOTS-c added to cultured myotubes and hepatocytes activates AMPK and shifts substrate utilisation in a way that is measurable by extracellular flux analysis within hours. SS-31 concentrates in the inner mitochondrial membrane through its cardiolipin affinity and improves respiratory efficiency in isolated mitochondria and permeabilised fibres — one of the few compounds in this area where the mechanism and the readout are directly linked. Senescence assays with FOXO4-DRI show reduced viability in senescent but not proliferating fibroblasts, which is the selectivity claim the compound rests on. GHK in fibroblast culture remains the most reproduced result of any peptide discussed here.
Model organisms
Invertebrate and rodent lifespan work is slow, expensive and, in this field, unevenly reported. The nutrient-sensing literature — caloric restriction, insulin/IGF-1 signalling, mTOR inhibition — is by far the most robust and is where rapamycin's reputation comes from. Peptide-specific lifespan data is thinner: epitalon has published rodent lifespan and tumour-incidence results from the Khavinson programme; MOTS-c has reported effects on physical capacity in aged mice; FOXO4-DRI has the 2017 mouse clearance data. Group sizes across this literature are frequently small and survival curves are not always accompanied by healthspan measures.
Human studies
Elamipretide is the only peptide here with a substantial registered trial programme, in primary mitochondrial myopathy and related conditions, and it has not achieved marketing approval. NAD precursor trials with NMN and NR consistently show that blood NAD+ metabolites rise, with functional endpoints remaining inconsistent. GHK-Cu has controlled topical dermatological data. Everything else on this page has no controlled human efficacy evidence.
Comparison table: reference compounds by hallmark
| Compound | Class | MW | Hallmark addressed | Evidence depth | Research sizes |
|---|---|---|---|---|---|
| Epitalon | Tetrapeptide, pineal | 390.35 Da | Telomere attrition | Extensive but single-network | 10-100 mg |
| MOTS-c | Mitochondrial-derived | 2174.55 Da | Mitochondrial dysfunction | Growing, multi-group | 5-40 mg |
| Humanin | Mitochondrial-derived | 2687.27 Da | Apoptosis, proteostasis | Two decades, multi-group | 5 mg, 10 mg |
| SS-31 (elamipretide) | Cardiolipin-binding tetrapeptide | 639.80 Da | Mitochondrial dysfunction | Human trial stage | 10-50 mg |
| FOXO4-DRI | D-retro-inverso senolytic | 6053 Da | Cellular senescence | One flagship paper | 10 mg |
| NAD+ | Redox cofactor | 663.43 Da | Nutrient sensing, sirtuin activity | Well replicated biochemically | 100-1000 mg |
| GHK-Cu | Copper matrikine | 403.93 Da | Extracellular matrix, gene expression | Fifty years, multi-group | 10-500 mg |
| L-Glutathione | Tripeptide antioxidant | 307.32 Da | Redox balance | Extensive as a cofactor | 600 mg, 1500 mg |
The evidence column is a judgement about how much independent replication exists, not about magnitude of effect. It is included because that variable does more to determine whether a study will survive review than any specification on the vial.
How researchers choose peptides for anti-aging research
- Which hallmark is the experiment testing? This settles most of the selection on its own. A senescence question needs a senolytic and a senescence readout; a bioenergetics question needs a mitochondrial peptide and an oxygen consumption measurement.
- Is the model long-lived enough? Telomere and lifespan work needs organisms and timeframes that cell culture cannot supply. Cultured human fibroblasts have their own replicative limits that confound telomere readouts.
- What is the control? Scrambled-sequence controls are standard for the short peptides and are the single most useful addition to a protocol in this area. For the D-retro-inverso senolytic, the L-form parent is the informative comparator.
- Does the compound reach the compartment? Mitochondrial peptides need to reach mitochondria. SS-31's cardiolipin affinity is the reason it does; assuming the same of the others without measuring it is a common gap.
The full catalogue for this goal is at peptides for anti-aging, and the broader mechanistic grouping including NAD, senolytic and mitochondrial reagents is under longevity and cellular health. Dermal aging endpoints are handled separately in our skin research overview.
Formats and handling
Lyophilised vials dominate because they allow molar concentrations to be set at reconstitution — essential when comparing compounds whose molecular weights span 307 Da to over 6,000 Da. Oral capsule formats exist for epitalon, GHK-Cu and NAD+, and for the small-molecule cofactors where oral bioavailability is established. Nasal formats are pre-diluted and fix concentration. The Khavinson bioregulator series is supplied both as vials and as encapsulated peptide extracts, which are chemically distinct preparations and should not be regarded as equivalent in a protocol.
Handling notes that matter in this group: NAD+ solutions oxidise and are light-sensitive, so they are prepared fresh and protected from light. Epitalon is a small, stable tetrapeptide and is among the more forgiving reagents here. FOXO4-DRI, at 6 kDa and in an all-D configuration, is the most expensive and the least tolerant of repeated freezing and thawing — aliquot at reconstitution. All lyophilised material is stored sealed at -20 °C or below and brought to room temperature before opening.
Common design errors in this area
The first is the single-readout claim: reporting one hallmark marker and describing the result as an anti-aging effect. The hallmarks are mechanistically separable and frequently move independently, so a change in senescence-associated beta-galactosidase staining says nothing about telomere length or respiratory capacity.
The second is confounded telomere measurement. Cultured primary human fibroblasts approach their own replicative limit during a long experiment, and qPCR-based telomere length assays are notoriously sensitive to DNA quality and to the reference gene chosen. Studies reporting telomere effects without flow-FISH or terminal restriction fragment confirmation are weak evidence.
The third is compartment assumption. A peptide catalogued as mitochondrial does not automatically reach mitochondria; SS-31 does so because of a defined cardiolipin interaction, and the same should be demonstrated rather than assumed for the others. Fluorescent-label uptake work is the usual way to close that gap.
The fourth is omitting the scrambled-sequence control. For short peptides this control costs little and rules out a large fraction of vehicle, counter-ion and impurity artefacts. Its absence is the most common reason a reviewer sends this kind of manuscript back.
Purity, identity and regulatory status
Short peptides in this class should show 98% or better by HPLC with mass-spectrometric identity confirmation. For epitalon and the other tetrapeptides, the theoretical mass is low enough that a mass spectrum is unambiguous, so there is no excuse for a COA without one. For FOXO4-DRI, confirm that the material is the D-retro-inverso construct rather than the L-form, since the two have the same nominal mass and are not interchangeable.
No compound described here is approved as an anti-aging intervention in the United States or the European Union. Elamipretide has been studied in registered human trials but holds no marketing approval. Rapamycin and metformin, frequently catalogued alongside these peptides in longevity protocols, are prescription-only medicines listed here for reference; their inclusion in a research catalogue is not a suggestion of use. Everything referenced on this page is research-grade material for in-vitro and laboratory use only.